Inhibition of proteasome activity, nuclear factor-KB translocation and cell survival by the antialcoholism drug disulfiram
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The proteasome pathway is an important target for anticancer drug development. Here, we identify the antialcoholism drug disulfiram and its analogue pyrrolidine dithiocarbamate (PDTC) as inhibitors of the 26S proteasome activity in a cell-based screening assay. As expected for proteasome inhibitors, these compounds also inhibited TNF-alpha-induced nuclear factor-KappaB (NF-KappaB) translocation and were cytotoxic. Disulfiram was more cytotoxic against chronic lymphocytic leukemia cells compared to peripheral blood mononuclear cells (PBMC) at clinically achievable concentrations. Proteasome and NF-KappaB inhibition were achieved with a potency in the same range as that of the clinically used proteasome inhibitor bortezomib. Disulfiram was also able to induce accumulation of p27(Kip1) and to prolong the half-life of c-Myc, both targets for proteasome-dependent degradation. It is concluded that the previously observed antitumoral and NF-KappaB inhibiting activity of disulfiram and PDTC could be attributed to their inhibition of the 26S proteasome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells.
Schreck, R., Meier, B., Männel, D. N., Dröge, W., & Baeuerle, P. A. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.5.1181 · Cited by 1,508 · cited 2×
“In our cell-based model system, PDTC itself inhibits the proteasome activity and this could provide an alternative explanation for the NF-KB-inhibiting activity of PDTC usually attributed to its antioxidant effect.(7)”
Background
Cited by
Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4
Skrott, Z., Mistrik, M., Andersen, K. K., Friis, S., Majera, D., Gursky, J., Ozdian, T., Bartkova, J., Turi, Z., Moudry, P., et al. (2017) · Nature · doi:10.1038/nature25016 · Cited by 807
Chen, D., Cui, Q. C., Yang, H., & Dou, Q. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2126 · Cited by 674
Duan, X., Xiao, J., Yin, Q., Zhang, Z., Yu, H., Mao, S., & Li, Y. (2013) · ACS Nano · doi:10.1021/nn4010796 · Cited by 379
Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth
Lin, J., Haffner, M. C., Zhang, Y., Lee, B. H., Brennen, W. N., Britton, J., Kachhap, S. K., Shim, J. S., Liu, J. O., Nelson, W. G., et al. (2011) · The Prostate · doi:10.1002/pros.21247 · Cited by 194
“Recent reports have shown in vitro and in vivo tumor cell killing effects of DSF in various cancer cell line models including melanoma, leukemia, small lung cell cancer, osteosacroma, cervical adenocarcinoma, and colorectal adenocarcinoma cell lines [44–48] and an anecdotal report from a patient with metastatic ocular…”
Hou, S., Tiriac, H., Sridharan, B. P., Scampavia, L., Madoux, F., Seldin, J., Souza, G. R., Watson, D., Tuveson, D., & Spicer, T. P. (2018) · SLAS Discovery · doi:10.1177/2472555218766842 · Cited by 169
Metadata
- Authors
- Lövborg, H., Öberg, F., Rickardson, L., Gullbo, J., Nygren, P., & Larsson, R.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2005-10-04
- Volume
- 118
- Issue
- 6
- Pages
- 1577-1580
- ISSN
- 0020-7136 (ISSN-L)
- OpenAlex
- W2085092447
- Cited by
- 128
- References
- 1
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.